S&P 5007,765.36▼0.5% Nasdaq27,193.34▼1.2% Dow51,231.64▲0.1% Russell 2K2,794.13▲0.0% 10-Yr5.23%−5bp VIX15.41+0.33 WTI$91.10▲3.2% Gold$4,157.80▲0.4% EUR/USD1.122▼0.3% BTC$84,464▲1.8% Nikkei70,036▼0.9%
At close · Thu, Oct 8, 2026
Daily Market Updates.

US Markets

Home›US Markets›Equities›Wall Street researchers just used Claude to design a d…

Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

Reported · Written up by our desk · Equities

For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.

← Newer storyA Sterling Thesis: The Long-Term Silver Investment Case

More like this

US MarketsSpaceX, Anthropic and Nvidia Help Snap Tech Stocks Out of Their Recent Malaise
US MarketsTesla beats earnings projections after Musk floats SpaceX merger plan
US MarketsTesla Profit Slumps as Elon Musk’s Car Company Considers Merging With SpaceX
US MarketsSouthwest Airlines cuts 2026 profit forecast on higher fuel
US MarketsOne of Your Fuel Bills Is Poised to Be Lower This Year

Sources

MarketWatchWall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.
MarketWatchWall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.